Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20958155 | 0.89 | MEN1 (0.44) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 | |
| SCHEMBL13779864 | 0.88 | MAPT (0.46) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 | |
| SCHEMBL20958154 | 0.88 | MAPT (0.45) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 | |
| SCHEMBL6562723 | 0.87 | KMT2A (0.43) | MAPTKDM4ECYP3A4ALDH1A1KMT2A | |
| SCHEMBL22522294 | 0.86 | MAPT (0.42) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 | |
| SCHEMBL823830 | 0.82 | ALDH1A1 (0.50) | MAPTKDM4ECYP3A4ALDH1A1KMT2A | |
| SCHEMBL8577525 | 0.82 | KMT2A (0.44) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 | |
| SCHEMBL10846219 | 0.81 | MAPT (0.45) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 | |
| SCHEMBL30766429 | 0.81 | ALDH1A1 (0.60) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 | |
| SCHEMBL1161468 | 0.81 | ALDH1A1 (0.60) | MAPTKDM4ECYP3A4ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030230478-A1 | Process for the preparation of 1,4 - dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2003-12-18 | — | — | US | claimed |
| WO-2003099790-A1 | PROCESS FOR THE PREPARATION OF 1,4-DIHYDROPYRIDINES AND NOVEL 1,4-DIHYDROPYRIDINES USEFUL AS THERAPEUTIC AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-12-04 | — | — | WO | claimed |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | ARTESIAN THERAPEUTICS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1565472-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004033444-A1 | DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY | ARTESIAN THERAPEUTICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-0996870-B1 | IMPROVED DISSOLUTION INHIBITION RESISTS FOR MICROLITHOGRAPHY | DU PONT (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030230478-A1 | Process for the preparation of 1,4 - dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2003-12-18 | — | — | US | disclosed |
| US-6319648-B1 | USED FOR IMAGING MATERIALS OF SEMICONDUCTOR DEVICE | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-11-20 | — | — | US | disclosed |
| EP-0996870-A1 | IMPROVED DISSOLUTION INHIBITION RESISTS FOR MICROLITHOGRAPHY | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999004319-A1 | IMPROVED DISSOLUTION INHIBITION RESISTS FOR MICROLITHOGRAPHY | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-01-28 | — | — | WO | disclosed |
| US-4268510-A | DEMETHANIZATION, METABOLISM, RUMEN | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-05-19 | — | — | US | disclosed |
| EP-0010348-A1 | Heterocyclic trichloromethyl derivatives, process for their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030230478-A1 | Process for the preparation of 1,4 - dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents | HRH4, ODC1, OGDH | MAPT 1360/4885KDM4E 942/4885CYP3A4 112/4885 |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | MAPT 1575/4885KDM4E 1928/4885CYP3A4 1067/4885 |
| US-20070066619-A1 | Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity | CACNA1C, PDE3A, PDE3B | MAPT 2452/4885KDM4E 1728/4885CYP3A4 1569/4885 |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | PDE3A, PDE4A, PDE3B | MAPT 2619/4885KDM4E 3236/4885CYP3A4 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.